ProCE Banner Activity

Treatment of Veterans With Advanced NSCLC: Guidance on Current Clinical Strategies

Multimedia
Watch this on-demand Webcast from the CCO non-small-cell lung cancer VA live meeting series where Jonathan Dowell, MD, provides expert perspective on the optimal treatment of patients with advanced NSCLC, including discussion of the most recent clinical data and management of treatment-related adverse events.

Released: November 29, 2017

Expiration: November 28, 2018

No longer available for credit.

Share

Faculty

Lyudmila Bazhenova

Lyudmila Bazhenova, MD

Associate Clinical Professor of Medicine
Division of Hematology-Oncology
University of California, San Diego
Medical Director, UC San Diego Moores Cancer Center Infusion Center
San Diego, California

Jonathan Dowell

Jonathan Dowell, MD

Associate Professor of Internal Medicine
Department of Hematology/Oncology
University of Texas Southwestern Medical Center
Dallas, Texas

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AstraZeneca

Celgene

Genentech Roche Virology

Learning Objectives

  • Assess clinical, histologic, and molecular information to individualize the treatment of patients with advanced non-small-cell lung cancer
  • Integrate the latest guidelines and clinical data to the treatment of patients with advanced-stage non-small-cell lung cancer based on tumor histology
  • Apply the latest guidelines and clinical data to the treatment of patients with advanced-stage non-small-cell lung cancer based on molecular markers
  • Manage treatment-related adverse events in patients with advanced non-small-cell lung cancer

Program Director Disclosure

Program Director

Lyudmila Bazhenova, MD

Associate Clinical Professor of Medicine
Division of Hematology-Oncology
University of California, San Diego
Medical Director, UC San Diego Moores Cancer Center Infusion Center
San Diego, California

Lyudmila Bazhenova, MD, has disclosed that she has received consulting fees from AstraZeneca, Lilly, Novartis, and Takeda; funds for research support from BeyondSpring Pharmaceuticals; and holds ownership interests with Epic Sciences.

Jonathan Dowell, MD

Associate Professor of Internal Medicine
Department of Hematology/Oncology
University of Texas Southwestern Medical Center
Dallas, Texas

Jonathan Dowell, MD, has disclosed that he has received consulting fees from AstraZeneca and Guardant Health and funds for research support from Astex, AstraZeneca, and Genentech.

Faculty Disclosure

Primary Author

Jonathan Dowell, MD

Associate Professor of Internal Medicine
Department of Hematology/Oncology
University of Texas Southwestern Medical Center
Dallas, Texas

Jonathan Dowell, MD, has disclosed that he has received consulting fees from AstraZeneca and Guardant Health and funds for research support from Astex, AstraZeneca, and Genentech.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.

Megan K. Murphy, PhD

Scientific Director

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.